Watson sees future in India
Watson Pharmaceuticals has acquired India's Sekhsaria Chemicals in a move to push forward its generic drug agenda.
Archives for April 17, 2006
Reata completes new anti-inflammatory drugs agreement
The possibility of a new class of anti-inflammatory compounds that exhibit broad action across multiple therapeutic sites could be on the horizon after Reata announced the completion of a license agreement for these drug candidates that are currently...
Affordable automation of small clinical trials
A new interactive voice response (IVR) package is available for small clinical trials, aimed at companies who previously found this technology unaffordable.
AppTec and Chromos expand relationship
AppTec Laboratory Services has signed a new contract to manufacture Chromos Molecular Systems's new multiple sclerosis (MS) drug for pre-clinical safety and toxicology studies.
Dowpharma signs fourth deal for Pfenex technology
Contract manufacturing services provider Dowpharma, has signed a collaboration agreement for its Pfenex Expression Technology, its fourth agreement in 1Q 2006, signifying the technology's popularity in developing new vaccines and biotherapeutics products.
ESA Biosciences' HPLC detector optimised for polymer analysis
ESA Biosciences make available its HPLC detection tool that is designed for laboratories that use THF (tetrahydrofuran) as a component in chromatographic separations and sample analyses.
Scientists develop technique to target brain tumour growth
A team of researchers have developed a strategy in which genes linked to cancer mutations could easily be identified aiding predictions as to which patient will respond favourably to novel drug treatments.
Stem cell use set to rise despite objections
Despite lingering ethical, legal and social concerns, the application of stem cell research in drug discovery and development is set to play a greater role as areas of unmet medical needs will need to be addressed as rates of incidence continue to rise.
American Peptide Company wins new deal
American Peptide Company (APC) has entered into a manufacturing agreement with Affymax for the clinical supply of the first in its pipeline of peptide-based drugs.